Literature DB >> 1276306

Heart-rate decelerative Pavlovian conditioning with tilt as UCS: towards behavioural control of cardiac dysfunction.

J J Furedy, C X Poulos.   

Abstract

As part of a programme the ultimate goal of which is to teach behavioural control of stress-induced maladaptive cardiac accelerations through Pavlovian decelerative conditioning, this study was directed at examining the feasibility of using tilting of the body from a head-up to a head-down position as the unconditional stimulus (UCS) to elicit phasic cardiac deceleration as the unconditional response (UCR). Experiment I assessed the reflexive features of the cardiac response to 32 tilt UCS trials delivered at mean intervals of 75 sec. The results yielded a large-magnitude (over 30 BsPM) cardiac decelerative UCR with fast recruitment and complete resistance to habituation. Experiment II examined the feasibility of using the tilt UCS to demonstrate associative control over decelerative responding to a tone as the conditional stimulus (CS). Relative to a control 'backward' UCS-CS group with an interstimulus interval (ISI) of 14.5 sec, a 0.5 sec ISI CS-UCS experimental group demonstrated both orderly acquisition and extinction performance. The magnitude of the conditional deceleration of some 4 BsPM is greater than the extent of control generally achieved with biofeedback, but still constitutes a problem for theoretical accounts of classical conditioning framed in terms of stimulus substitution, and is still only of borderline clinical significance.

Entities:  

Mesh:

Year:  1976        PMID: 1276306     DOI: 10.1016/0301-0511(76)90010-7

Source DB:  PubMed          Journal:  Biol Psychol        ISSN: 0301-0511            Impact factor:   3.251


  11 in total

Review 1.  Reflections on human Pavlovian decelerative heart-rate conditioning with negative tilt as US: alternative approaches.

Authors:  J J Furedy
Journal:  Integr Physiol Behav Sci       Date:  1992 Oct-Dec

Review 2.  Some recalcitrant views on the role of noncognitive S-R factors in human Pavlovian autonomic conditioning. Some facts still haunt us.

Authors:  J J Furedy
Journal:  Integr Physiol Behav Sci       Date:  1991 Jan-Mar

3.  Resting parasympathetic status and cardiovascular response to orthostatic and behavioral challenges in type I insulin-dependent diabetes mellitus.

Authors:  B E Hurwitz; R E Quillian; J B Marks; N Schneiderman; R F Agramonte; C R Freeman; A M La Greca; J S Skyler
Journal:  Int J Behav Med       Date:  1994

4.  Psychophysiological and physiological aspects of T-wave amplitude in the objective study of behavior.

Authors:  J J Furedy; R J Heslegrave; H Scher
Journal:  Pavlov J Biol Sci       Date:  1984 Oct-Dec

5.  Revisiting the learning-without-awareness question in human Pavlovian autonomic conditioning: focus on extinction in a dichotic listening paradigm.

Authors:  J J Furedy; B Damke; W Boucsein
Journal:  Integr Physiol Behav Sci       Date:  2000 Jan-Mar

6.  An experimental psychophysiological approach to human bradycardiac reflexes.

Authors:  J J Furedy
Journal:  Pavlov J Biol Sci       Date:  1985 Apr-Jun

7.  Blood pressure changes validate phase related external suction, a controlled method for stimulation of human baroreceptors.

Authors:  H Rau; S Brody; C Droste; A Kardos
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1993

8.  Assessing fear learning via conditioned respiratory amplitude responses.

Authors:  Giuseppe Castegnetti; Athina Tzovara; Matthias Staib; Samuel Gerster; Dominik R Bach
Journal:  Psychophysiology       Date:  2016-12-08       Impact factor: 4.016

9.  Modeling fear-conditioned bradycardia in humans.

Authors:  Giuseppe Castegnetti; Athina Tzovara; Matthias Staib; Philipp C Paulus; Nicolas Hofer; Dominik R Bach
Journal:  Psychophysiology       Date:  2016-03-07       Impact factor: 4.016

10.  Conditioned increase of locomotor activity induced by haloperidol.

Authors:  Luis Gonzalo De la Casa; Lucía Cárcel; Juan Carlos Ruiz-Salas; Lucía Vicente; Auxiliadora Mena
Journal:  PLoS One       Date:  2018-10-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.